1. Generics Bulletin

First US Eliquis Generics Face Six-Year Wait

Mylan And Micro Labs Have Settled With BMS Over Apixaban

 
• By Akriti Seth

Mylan and Micro Labs have received the first FDA approvals for generic rivals to BMS’ Eliquis oral anticoagulant. However, as a result of the firms’ settlements with the originator, BMS does not expect the generics to hit the US market until 2026.

Skydiver_2026
BMS expects its Eliquis exclusivity to fall in 2026 • Source: Shutterstock

Mylan and Micro Labs have received the first approvals from the US Food and Drug Administration for generic rivals to Bristol-Myers Squibb’s Eliquis (apixaban) 2.5mg and 5mg tablets. Janet Woodcock, director of the FDA’s center for drug evaluation and research, noted that the abbreviated new drug application approvals “mark the first generic approvals of a direct oral anticoagulant.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation